Researchers at the University of North Carolina at Chapel Hill and North Carolina State University have uncovered a novel approach to creating inhalable vaccines using nanoparticles that shows promise for targeting lung-specific diseases, such as influenza, pneumonia and tuberculosis.
The work, led by Cathy Fromen and Gregory Robbins, members of the DeSimone and Ting labs, reveals that a particle’s surface charge plays a key role in eliciting immune responses in the lung. Using the Particle Replication in Nonwetting Templates (PRINT) technology invented in the DeSimone lab, Fromen and Robbins were able to specifically modify the surface charge of protein-loaded particles while avoiding disruption of other particle features, demonstrating PRINT’s unique ability to modify particle attributes independently from one another.
When delivered through the lung, particles with a positive surface charge were shown to induce antibody responses both locally in the lung and systemically in the body. In contrast, negatively charged particles of the same composition led to weaker, and in some cases undetectable, immune responses, suggesting that particle charge is an important consideration for pulmonary vaccination.
The Latest on: Inhalable vaccines
via Google News
The Latest on: Inhalable vaccines
- Translate Bio plans Covid-19 vaccine trial, considers inhalable versionon June 24, 2020 at 11:12 am
French drug giant Sanofi has given local startup Translate Bio another $425 million to develop vaccines, including one for Covid-19 that could be tested in humans later this year. Lexington’s ...
- Race for breakthrough coronavirus vaccine: What advances have been made and when will one be made available?on June 23, 2020 at 7:30 pm
"Vaccine breakthrough" - the two words the country is waiting to hear as we face many months of living with Covid-19. More than 100 potential vaccines are under development in an intense race to ...
- Sanofi Moves Up Target For Its COVID-19 Vaccine; Gilead Doubles Estimate Of Remdesivir Productionon June 23, 2020 at 10:48 am
French drugmaker Sanofi SA (SASY.PA) said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain’s GlaxoSmithKline Plc (GSK.L) by the first half of next ...
- Tear-Gassing Protesters During an Infectious Outbreak ‘A Recipe for Disaster’on June 23, 2020 at 12:10 am
Their widespread use in recent weeks while an infectious disease — for which there is no vaccine — continues to spread across the U.S., has stunned experts and physicians. The coronavirus that causes ...
- Gilead to study inhalable form of remdisivir - a possible COVID-19 breakthroughon June 22, 2020 at 8:57 pm
The pharmaceutical company that makes the antiviral drug remdesivir, which has shown promise as a treatment for COVID-19, will begin trials for an inhalable version of the medication this summer as ...
- Federal legislation seeks to prevent ‘pandemic profiteering’on June 22, 2020 at 12:25 pm
The bills aim to ensure that treatments and a vaccine for COVID-19 are affordable, and that taxpayer funding of drug research is more transparent.
- Tear-Gassing Protesters During An Infectious Outbreak 'A Recipe For Disaster'on June 6, 2020 at 7:16 am
Their widespread use in recent weeks while an infectious disease — for which there is no vaccine — continues ... Deploying these corrosive, inhalable chemicals could harm people in several ...
- When will you get a vaccine?on May 18, 2020 at 5:53 pm
Those are hypotheticals but that is how it works sometimes — for instance with flu vaccines, sometimes there is an inhalable that works better than an injectable for young and healthy people.
via Bing News